Loading
Latest filing published 01 Sept 2026 for Quoin Pharmaceuticals, Ltd., €86k.
Based on 5 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Denise P. Carter is a declared insider of Quoin Pharmaceuticals, Ltd., with filings sourced from SEC (Form 4). Over a trading history stretching from 3 September 2024 to 31 August 2026, the count stands at 6 filings.
Purchases make up the whole of the open-market record (6 purchases, €352k). Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2026 alone, the filings show 1 purchase and no sales.
A typical purchase (the median) is worth €11k. On 6 out of 6 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 5 purchases show a median change of -2.6%, with the price up in 0% of them. These figures describe past trades and do not predict future prices.
Most recently, on 1 September 2026, the filings show an open-market purchase worth €86k in Quoin Pharmaceuticals, Ltd. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations